Viz.ai
AI that flags suspected strokes on scans and pages the care team
Overview
Viz.ai is a San Francisco company whose platform reads CT scans, ECGs and other data for suspected strokes and other urgent conditions, then alerts and coordinates the treating team on mobile and desktop. It holds 13 FDA clearances, runs more than 50 AI care pathways in about 2,000 US hospitals, and is sold to health systems by quote.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 14 Oct 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Dedicated 24/7 on-call clinical specialists
- Implementation experts and customer success team
- Mobile and desktop alerts for care teams
Use cases
What you can produce with Viz.ai
- Automatic detection of suspected large-vessel-occlusion strokes on CT, with alerts to the stroke team
- Mobile and desktop notifications with scan images for the treating specialists
- Hemorrhage, aneurysm, pulmonary embolism and aortic disease detection pathways
- ECG-based flags for hypertrophic cardiomyopathy and other cardiac conditions
- Pulmonary care pathways for COPD, lung nodules and pulmonary embolism
- Custom AI care pathways built in plain language with Viz Agent Studio
ASEAN Perspective
Viz.ai in Southeast Asia
Viz.ai's clinical evidence base is drawn almost entirely from U.S. and European hospital networks, and no confirmed ASEAN or Asia-Pacific hospital deployments have been publicly announced as of mid-2026. Stroke burden in Southeast Asia is high — ASEAN countries account for a disproportionate share of global stroke mortality — making the platform's core use case directly relevant, but local regulatory clearances (HSA Singapore, BPOM Indonesia, Thai FDA, PMDA Japan) would need to be obtained before commercial deployment. Health systems in Singapore, Thailand, and Malaysia that wish to pilot AI stroke triage should also evaluate RapidAI and Aidoc, both of which have more documented APAC reference sites and may present lower localisation hurdles.
Viz.ai pioneered AI stroke triage, and its 2018 De Novo authorisation is still the reference point for the category. Today it is a broad care-coordination platform in about 2,000 US hospitals, with 13 FDA clearances behind more than 50 care pathways and a tool for hospitals to build their own. Read its marketing carefully: the homepage's "50+ FDA-cleared algorithms" is not what its own July 2026 release says, and headline outcome figures are often single-site, company-announced results.
Pricing is by quote only, and with no disclosed Asian deployments, ASEAN hospitals would need local regulatory clearance before using it.
What we found
Viz.ai started with one job: when a CT scan suggests a large-vessel-occlusion stroke, alert the specialist team on their phones instead of waiting for a radiologist to read it. The FDA authorised that software, then called ContaCT and now Viz LVO, through the De Novo route in February 2018, and Viz.ai describes it as the first clearance of its kind for AI triage. Set up in 2016 by neurosurgeon Chris Mansi and David Golan, the San Francisco company has since expanded into cardiology, vascular disease, trauma, oncology and, from May 2026, a pulmonary suite covering COPD, lung nodules and pulmonary embolism.
Its count of approvals needs care. The homepage says the platform runs on more than 50 FDA-cleared algorithms, but Viz.ai's own July 2026 anniversary release gives 13 FDA clearances and more than 50 AI care pathways; earlier versions of this page repeated the larger figure. The same release puts it in 2,000 US hospitals covering an estimated 230 million people, with 14 life-sciences partners and more than 125 publications, and says Viz.ai was the first company to receive Medicare new-technology add-on payment for AI software.
Outcome figures are mostly company-announced. A March 2026 release reported a 44% cut in door-in-door-out time for stroke transfers at one regional centre, from 202 to 113 minutes, but the deployment came with a new hospital partnership and standard transfer protocols, so the gain is not Viz.ai's alone. Newer additions include Viz Agent Studio, which lets hospitals build their own AI pathways in plain language, ISO/IEC 42001 certification and a Cortechs.ai partnership on neurodegenerative disease. Viz.ai says its healthcare business turned profitable in 2025; its last disclosed round was a $100 million Series D in 2022 at a $1.2 billion valuation.
Prices are not published and sales go through demos. The company has entities in the Netherlands, the UK and Israel, but no Asian deployment is disclosed, so ASEAN hospitals would be early adopters needing local regulatory approval.
Compiled by RECATOOLS from public sources: vendor documentation and pricing, code repositories and published reporting.
Notable facts
- Viz.ai's 2018 FDA De Novo clearance was the first ever granted for an AI clinical decision support tool in emergency imaging triage.
- The platform assists in the care of one patient approximately every 32 seconds across its hospital network.
- Co-founder Dr. Chris Mansi was inspired to start the company after a patient died from delayed stroke treatment despite successful surgery.
- Viz.ai reached unicorn status ($1.2B valuation) in April 2022 led by Tiger Global and Insight Partners.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Viz.ai's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Viz.ai unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Viz.ai directly →
Spotted something out of date? Suggest an update →
More in Healthcare
